
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOcGVGdDl1aTBkdEJiSXRfQy00R0luWkN0WkE5d041Qlp5NUdCSGIxRncxM1ptdkM0Ym9nZXJVNkM3MWpDWE1YOW1jSWhVQjZ6QjBhbVZZY25kTWZBenBKU0xsaVQ5aUZpTW94RUVXN1o3VVZienU3TDFUanFLSTMzVFJpTEhmejU0Szdz?oc=5" target="_blank">Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial</a>&nbsp;&nbsp;<font color="#6f6f6f">The Lancet</font>
